Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy

Molecular and Cellular Biochemistry

Volumn 269, Issue 1, 2005, Pages 137-142

  Shirai, Ken ^a   Watanabe, Kenichi ^a   Ma, Meilei ^a   Wahed M I I , Mir I I ^a   Inoue, Mikio ^a   Saito, Yuki ^a   Suresh, Palaniyandi Selvaraj ^a   Kashimura, Takeshi ^b   Tachikawa, Hitoshi ^b   Kodama, Makoto ^b   Aizawa, Yoshifusa ^b  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blockade; Angiotensin II; Candesartan; Collagen III; Dilated cardiomyopathy; Heart failure; Transforming growth factor 1

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; COLLAGEN TYPE 3; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BODY WEIGHT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GENE REPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; HEART WEIGHT; IMMUNIZATION; MALE; MYOCARDITIS; NONHUMAN; PROTEIN EXPRESSION; RAT; RAT STRAIN; RECEPTOR BLOCKING;

ANGIOTENSIN II; ANIMALS; AUTOIMMUNE DISEASES; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; COLLAGEN TYPE III; MALE; MYOCARDITIS; MYOCARDIUM; RATS; RATS, INBRED LEW; RECEPTORS, ANGIOTENSIN; RNA, MESSENGER; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 20044377202     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11010-005-3446-9     Document Type: Article

References (25)

1. CONSENSUS trial study group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435, 1987
2. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M: A comparison of enarapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 324: 303-310, 1991
3. SOLVD investigators: Effects of enarapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-302, 1991
4. Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, Schunkert H, Benedict CR, Lorell BH: Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 90: 1410-1422, 1994
5. Litwin SE, Katz SE, Weinberg EO, Lorell BH, Aurigemma GP, Douglas PS: Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation 91: 2642-2654, 1995
6. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865, 1991 1:STN:280:By6B2cbkt1A%3D
7. Swynghedauw B: Molecular mechanisms of myocardial remodeling. Physiol Rev 79: 215-262, 1999
8. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245: 186-188, 1989
9. Schelling P, Fischer H, Ganten D: Angiotensin and cell growth: A link to cardiovascular hypertrophy? J Hypertens 9: 3-15, 1991
10. Pfeffer MA, Swedbelg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S; CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 362: 759-766, 2003 10.1016/S0140-6736(03)14282-1
11. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees: Effects of candesartan in patients with heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 362: 767-771, 2003 10.1016/ S0140-6736(03)14283-3
12. Ma M, Watanabe K, Wahed IIM, Inoue M, Sekiguchi T, Kouda T, Ohta Y, Nakazawa M, Yoshida Y, Yamamoto T, Hanawa H, Kodama M, Fuse K, Aizawa Y: Inhibition of progression of heart failure and expression of TGF-β1 mRNA in rats with heart failure by the ACE inhibitor quinapril. J Cardiovasc Pharmacol 38: S51-S54, 2001
13. Kodama M, Hanawa H, Saeki M, Hosono M, Inomata T, Suzuki K, Shibata A: Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 75: 278-284, 1994
14. Watanabe K, Ohta Y, Nakazawa M, Higuchi H, Hasegawa G, Naito M, Fuse K, Ito M, Hirono S, Tanabe N, Hanawa H, Kato K, Kodama M, Aizawa Y: Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 130: 1489-1495, 2000
15. Ohta Y, Watanabe K, Nakazawa M, Yamamoto T, Ma M, Fuse K, Ito M, Hirono S, Tanabe T, Hanawa H, Kato T, Kodama M, Aizawa Y: Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol 36(suppl 2): S19-S23, 2000
16. Chomczynski P, Sacchi N: Single-step method of mRNA by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987
17. Fujinaka H, Yamamoto T, Feng L, Kawasaki K, Yaoita E, Hirose S, Goto S, Wilson CB, Uchiyama M, Kihara I: Crucial role of CD8-positive lymphocytes in glomerular expression of ICAM-1 and cytokines in crescentic glomerulonephritis of WKY rats. J Immunol 158: 4978-4983, 1997
18. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 362: 772-776, 2003 10.1016/S0140-6736(03)14284-5
19. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 362: 777-781, 2003
20. Juan W, Nakazawa M, Watanabe K, Ma M, Wahed IIM, Hasegawa G, Naito M, Yamamoto T, Fuse K, Kato K, Kodama M, Aizawa Y: Quinapril inhibits progression of heart failure and fibrosis in rats with dilated cardiomyopathy after myocarditis. Mol Cell Biochem 251: 77-82, 2003
21. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H: Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 25: 1252-1259, 1995
22. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, Iwao H: Angiotensin II type I receptor antagonist inhibits the gene expression of transforming grows factor-β1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 273: 509-515, 1995
23. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T, Komuro I: Mechanical stress activates angiotensin II type I receptor without the involvement of angiotensin II. Nat Cell Biol 6(6): 499-506, 2004
24. Kashimura T, Hayashi M, Kodama M, Nakazawa M, Abe S, Yoshida T, Tachikawa H, Hanawa H, Kato K, Watanabe K, Aizawa Y: Effects of imidapril and TA-606 on rat dilated cardiomyopathy after myocarditis. Jpn Heart J 44: 735-744, 2003
25. Godsel LM, Leon JS, Wang K, Fornek JL, Molteni A, Engman DM: Captopril prevents experimental autoimmune myocarditis. J Immunol 171: 346-352, 2003